Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials

Cancer

Volumn 118, Issue 18, 2012, Pages 4571-4578

  Pentz, Rebecca D ^a   White, Margaret ^b   Harvey, R Donald ^a   Farmer, Zachary Luke ^c   Liu, Yuan ^d   Lewis, Colleen ^a   Dashevskaya, Olga ^a   Owonikoko, Taofeek ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

clinical trials; ethics; informed consent; phase 1; therapeutic misconception

Indexed keywords

ADULT; AGED; ALTRUISM; ARTICLE; CLINICAL PROTOCOL; CLINICAL RESEARCH; EDUCATION; FEMALE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MOTIVATION; OPTIMISM; PESSIMISM; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THERAPEUTIC MISCONCEPTION;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE I AS TOPIC; COMPREHENSION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMED CONSENT; MALE; MIDDLE AGED; RISK ASSESSMENT; THERAPEUTIC MISCONCEPTION;

EID: 84865974488     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27397     Document Type: Article

References (39)

1. Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M,. Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol. 1992; 10: 1810-1816.
2. Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995; 13: 1062-1072.
3. Emanuel EJ,. A phase I trial on the ethics of phase I trials. J Clin Oncol. 1995; 13: 1049-1051.
4. Agrawal M, Emanuel EJ,. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA. 2003; 290: 1075-1082.
5. Joffe S, Miller FG,. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol. 2006; 24: 2987-2990.
6. Schaeffer MH, Krantz DS, Wichman A, Masur H, Reed E, Vinicky JK,. The impact of disease severity on the informed consent process in clinical research. Am J Med. 1996; 100: 261-268.
7. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC,. Quality of informed consent: a new measure of understanding among research subjects. J Natl Cancer Inst. 2001; 93: 139-147.
8. Daugherty CK, Banik DM, Janish L, Ratain MJ,. Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB. 2000; 22: 6-14.
9. Itoh K, Sasaki Y, Fujii H, et al. Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. Br J Cancer. 1997; 76: 107-113.
10. Rodenhuis S, van den Heuvel WJ, Annyas AA, Koops HS, Sleijfer DT, Mulder NH,. Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol. 1984; 20: 457-462.
11. Kass N, Fogarty L, Sugarman J, et al. An intervention to improve cancer patient's understanding of early-phase clinical trials. IRB. 2009; 31: 1-10.
12. Miller FG, Joffe S,. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clin Trials. 2008; 5: 617-623.
13. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005; 352: 895-904.
14. Miller FG, Joffe S,. Evaluating the therapeutic misconception. Kennedy Inst Ethics J. 2006; 16: 353-366.
15. Appelbaum PS, Lidz CW,. Re-evaluating the therapeutic misconception: response to Miller and Joffe. Kennedy Inst Ethics J. 2006; 16: 367-373.
16. Kass NE,. Early phase clinical trials: communicating the uncertainties of "magnitude of benefit" and "likelihood of benefit." Clin Trials. 2008; 5: 627-629; discussion 630.
17. Horng S, Grady C,. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB. 2003; 25: 11-16.
18. Weinfurt KP, Sulmasy DP, Schulman KA, Meropol NJ,. Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theor Med Bioeth. 2003; 24: 329-344.
19. Jansen LA, Appelbaum PS, Klein WM, et al. Unrealistic optimism in early-phase oncology trials. IRB. 2011; 33: 1-8.
20. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W,. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep. 1987; 17: 20-24.
21. Appelbaum PS, Roth LH, Lidz C,. The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry. 1982; 5: 319-329.
22. Henderson GE, Churchill LR, Davis AM, et al. Clinical trials and medical care: defining the therapeutic misconception [serial online]. PLoS Med. 2007; 4: e324.
23. Wendler D, Grady C,. What should research participants understand to understand they are participants in research? Bioethics. 2008; 22: 203-208.
24. Weinfurt KP, Seils DM, Tzeng JP, et al. Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making. 2008; 28: 575-581.
25. Cohen L, de Moor C, Amato RJ,. The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial. Cancer. 2001; 91: 1949-1955.
26. Helft PR, Hlubocky F, Wen M, Daugherty CK,. Associations among awareness of prognosis, hopefulness, and coping in patients with advanced cancer participating in phase I clinical trials. Support Care Cancer. 2003; 11: 644-651.
27. Jansen LA,. The problem with optimism in clinical trials. IRB. 2006; 28: 13-19.
28. Sugarman J, Kass NE, Goodman SN, Perentesis P, Fernandes P, Faden RR,. What patients say about medical research. IRB. 1998; 20: 1-7.
29. Weinfurt KP, Castel LD, Li Y, et al. The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer. 2003; 98: 166-175.
30. Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ,. Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol. 2006; 24: 4479-4484.
31. Kim SY, Holloway RG, Frank S, et al. Volunteering for early phase gene transfer research in Parkinson disease. Neurology. 2006; 66: 1010-1015.
32. Kim SY, Holloway RG, Frank S, Wilson R, Kieburtz K,. Trust in early phase research: therapeutic optimism and protective pessimism. Med Health Care Philos. 2008; 11: 393-401.
33. Hawryluck L,. People at the end of life are a vulnerable research population. Clin Oncol (R Coll Radiol). 2004; 16: 225-226.
34. Nickel PJ,. Vulnerable populations in research: the case of the seriously ill. Theor Med Bioeth. 2006; 27: 245-264.
35. Decoster G, Stein G, Holdener EE,. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990; 1: 175-181.
36. Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN,. Design and results of phase I cancer clinical trials: 3-year experience at M. D. Anderson Cancer Center. J Clin Oncol. 1996; 14: 287-295.
37. King NM,. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics. 2000; 28: 332-343.
38. Seidenfeld J, Horstmann E, Emanuel EJ, Grady C,. Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med. 2008; 168: 16-20.
39. Jenkins V, Solis-Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ,. What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J Clin Oncol. 2011; 29: 61-68.